sØren bregenholt barbara araneo corporate ... - novo … · • prevention/progression offor more...
TRANSCRIPT
Partnering for
innovationNovo Nordisk is seeking potential partners who can help us to improve patient therapy by discovering innovative peptide- and protein-based therapeutics for treatment of• DIABETES • OBESITY• DIABETIC LATE COMPLICATIONS• PROTEIN TECHNOLOGIES• HAEMOPHILIA
ANAND GAUTAMInnovation scouting director
Denmark
Discover more about Partnering for innovation at http://www.novonordisk.com/rnd/partnering
TOMAS LANDHSenior Principal Scientist
Denmark
JØRN ROLAND MÜLLERInnovation Sourcing Director
Denmark
BARBARA ARANEOInnovation Sourcing Director
USA
MARTIN E. JUDGE Innovation Sourcing Directorr
Denmark
ANAND GAUTAMInnovation Sourcing Director
Denmark
SØREN BREGENHOLTCorporate Vice President
Denmark
CHUCK GRAYInnovation Sourcing Director
USA
IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES
Diabetes Insulin and GLP-1 receptor peptide-agonists: •InsulinsandGLP-1swithnoveltherapeutic properties o Optimised for oral delivery o Modified duration of action o Improved side-effect profileTherapeuticproteinsandpeptidesaffecting: •Glucoseregulation o With anti-obesity effects, and/or anti-hyperlipidaemia,and/or anti-atheroscleroticeffects o Withoutinducinghypoglycaemia,and/or inducingweightgain •Insulinsecretion •Insulinresistance •Beta-cellmass •Inflammationrelatedtodiabetesandobesity •Prevention/progressionofdiabetes
Obesity Protein peptides for obesity treatment: •Addressingcomorbidities •Affectinge.g. o Appetite regulation o Energy expenditure
Looking for
JØ[email protected]+45 30751988
[email protected]+1 8453237463
+45 30757115
[email protected]+45 30797971
[email protected]+45 30797988
+1 2064738289
Haemophilia •Longerdurationofactionofcoagulation factors •Novelbypassingprinciples •Toleranceandimmunogenicity •Jointhealth
Humangrowthhormonedisorders •LongerdurationofactionofhGH •Oraldelivery
Diabetic late complications •Novelbiologicstotreatmicrovascular complications:o oDiabeticretinopathyo oDiabeticnephropathy
Newproteindeliverydevices •Injectionofsolubleproteinformulations •Reconstitutionandinfusionoflyophilised protein formulations
ProteintechnologiesProteinandpeptidetechnologies: •Expression •Modification •ProductionFormulationanddeliverytechnologies: •Liquid •Oral •Sustained/triggeredrelease
For more information about Novo Nordisk, visitnovonordisk.com
Orfollowuson